Most Shareholders Will Probably Find That The CEO Compensation For China Health Group Limited (HKG:673) Is Reasonable
Most Shareholders Will Probably Find That The CEO Compensation For China Health Group Limited (HKG:673) Is Reasonable
Key Insights
主要見解
- China Health Group to hold its Annual General Meeting on 12th of September
- Salary of HK$1.20m is part of CEO Ho Chung's total remuneration
- Total compensation is similar to the industry average
- Over the past three years, China Health Group's EPS fell by 45% and over the past three years, the total shareholder return was 8.5%
- 中國衛生集團將於9月12日舉行年度股東大會
- 年薪120萬港幣是CEO何中的總薪酬的一部分
- 總補償與行業平均水平相似
- 在過去三年中,中國衛生集團的每股收益下降了45%,而在過去三年中,總股東回報率爲8.5%
Despite China Health Group Limited's (HKG:673) share price growing positively in the past few years, the per-share earnings growth has not grown to investors' expectations, suggesting that there could be other factors at play driving the share price. The upcoming AGM on 12th of September may be an opportunity for shareholders to bring up any concerns they may have for the board's attention. It would also be an opportunity for them to influence management through exercising their voting power on company resolutions, including CEO and executive remuneration, which could impact on firm performance in the future. From what we gathered, we think shareholders should be wary of raising CEO compensation until the company shows some marked improvement.
儘管中國衛生集團(HKG:673)的股價在過去幾年裏有積極增長,但每股收益增長的速度未能達到投資者的預期,這表明股價可能受到其他因素的影響。即將於9月12日舉行的股東大會可能是股東們提出任何關注的機會,以引起董事會的注意。這也是他們通過行使投票權影響管理層的機會,包括對CEO和高級管理層報酬的投票,這可能影響公司未來的業績。根據我們收集的信息,我們認爲在公司顯示出明顯改善之前,股東們應該謹慎提高CEO的報酬。
How Does Total Compensation For Ho Chung Compare With Other Companies In The Industry?
賀中國的全額報酬如何與行業其他公司相比?
According to our data, China Health Group Limited has a market capitalization of HK$369m, and paid its CEO total annual compensation worth HK$1.2m over the year to March 2024. That's mostly flat as compared to the prior year's compensation. Notably, the salary which is HK$1.20m, represents most of the total compensation being paid.
據我們的數據,中國衛生集團有限公司的市值爲36900萬港元,其CEO在2023年年度期間總計獲得的報酬總值爲120萬港元。與上一年的報酬相比,基本持平。值得注意的是,這120萬港元的工資佔總報酬的大部分。
For comparison, other companies in the Hong Kong Healthcare industry with market capitalizations below HK$1.6b, reported a median total CEO compensation of HK$1.6m. From this we gather that Ho Chung is paid around the median for CEOs in the industry.
相比之下,香港醫療保健行業市值低於16億港元的其他公司,報告的CEO總報酬中位數爲160萬港元。由此我們可以得出結論,賀中國的報酬水平大約與行業的中位數相當。
Component | 2024 | 2023 | Proportion (2024) |
Salary | HK$1.2m | HK$1.2m | 99% |
Other | HK$18k | HK$26k | 1% |
Total Compensation | HK$1.2m | HK$1.2m | 100% |
組成部分 | 2024 | 2023 | 比例(2024年) |
薪資 | 120萬港元 | 120萬港元 | 99% |
其他 | HK$18k | 26,000港幣 | 1% |
總補償 | HKD 120萬 | 120萬港元 | 100% |
On an industry level, roughly 76% of total compensation represents salary and 24% is other remuneration. China Health Group pays a high salary, concentrating more on this aspect of compensation in comparison to non-salary pay. If salary dominates total compensation, it suggests that CEO compensation is leaning less towards the variable component, which is usually linked with performance.
從行業水平來看,大約76%的總薪酬是工資,24%是其他報酬。中國衛生集團支付高工資,與非工資報酬相比,更加重視這方面的報酬。如果工資佔據了總薪酬的主導地位,這意味着CEO的薪酬更少地傾向於可變的組成部分,而這通常與績效掛鉤。
China Health Group Limited's Growth
中國衛生集團有限公司的增長
China Health Group Limited has reduced its earnings per share by 45% a year over the last three years. In the last year, its revenue is down 22%.
中國衛生集團有限公司過去三年的每股收益下降了45%。在過去一年中,其營業收入下降了22%。
The decline in EPS is a bit concerning. And the fact that revenue is down year on year arguably paints an ugly picture. These factors suggest that the business performance wouldn't really justify a high pay packet for the CEO. While we don't have analyst forecasts for the company, shareholders might want to examine this detailed historical graph of earnings, revenue and cash flow.
EPS的下降有點令人擔憂。 年復一年的減少收入或許勾勒了一個不佳的畫面。 這些因素表明公司的業務表現不足以爲CEO提供高額薪酬。 雖然我們沒有公司的分析師預測,但股東可能要查看一下歷史收益,收入和現金流的詳細歷史圖表。
Has China Health Group Limited Been A Good Investment?
中國衛生集團有限公司是一個好的投資嗎?
China Health Group Limited has generated a total shareholder return of 8.5% over three years, so most shareholders wouldn't be too disappointed. Although, there's always room to improve. In light of that, investors might probably want to see an improvement on their returns before they feel generous about increasing the CEO remuneration.
中國衛生集團有限公司在三年內實現了8.5%的股東總回報,因此大多數股東不會太失望。儘管如此,總是有改善的空間。基於此,投資者可能希望在他們增加CEO薪酬前看到他們的回報有所改善。
In Summary...
總之……
China Health Group pays its CEO a majority of compensation through a salary. While it's true that shareholders have owned decent returns, it's hard to overlook the lack of earnings growth and this makes us question whether these returns will continue. In the upcoming AGM, shareholders will get the opportunity to discuss any concerns with the board, including those related to CEO remuneration and assess if the board's plan will likely improve performance in the future.
中國衛生集團通過工資向其首席執行官支付了大部分的薪酬。儘管股東取得了相當不錯的回報,但很難忽視盈利增長的缺乏,這使我們質疑這些回報是否會持續下去。在即將舉行的股東大會上,股東們將有機會討論與董事會有關的任何問題,包括與首席執行官薪酬相關的問題,並評估董事會的計劃是否有可能在未來改善業績。
We can learn a lot about a company by studying its CEO compensation trends, along with looking at other aspects of the business. That's why we did our research, and identified 3 warning signs for China Health Group (of which 1 is significant!) that you should know about in order to have a holistic understanding of the stock.
通過研究公司首席執行官薪酬趨勢以及其他業務方面,我們可以了解到很多關於公司的信息。這就是爲什麼我們進行了調查,並確定了中國衛生集團的3個警告信號(其中1個是重要的!),您應該了解這些信號,以全面了解該股票。
Important note: China Health Group is an exciting stock, but we understand investors may be looking for an unencumbered balance sheet and blockbuster returns. You might find something better in this list of interesting companies with high ROE and low debt.
重要提示:中國衛生集團是一隻令人興奮的股票,但我們明白投資者可能正在尋找一張無負債和超高回報的資產負債表。您可能會在這個有高roe和低債務的有趣公司名單中找到更好的產品。
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對本文有任何反饋?對內容有任何疑慮?請直接與我們聯繫。或者,發送電子郵件至editorial-team@simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。